The Stark Reality of Antibiotic Access in Low- and Middle-Income Countries
A recent study published in the Lancet Infectious Diseases paints a grim picture of antibiotic access: less than 7% of individuals with severe drug-resistant infections in poorer countries receive the necessary antibiotics. This alarming statistic not only contributes to considerable suffering and loss of life but is also driving antimicrobial resistance (AMR) — projected to cause 1.9 million deaths globally by 2050.
Global Crisis: Antimicrobial Resistance on the Rise
AMR, an increasingly dire public health threat, emerges when pathogens evolve to resist treatments typically used against them. Often fueled by antibiotic overuse, where greater drug exposure allows bacteria more opportunities to develop resistance, neglect of access in low- and middle-income nations has exacerbated this issue.
Researchers from the Global Antibiotic Research and Development Partnership (GardP) focused on countries across varying economic statuses, including Bangladesh, Egypt, India, Kenya, and Mexico. Their findings indicate an overwhelming shortage of appropriate antibiotic treatments — with availability as low as 0.2% in Kenya versus a mere 15% in Egypt and Mexico.
Parallel to HIV: A Call for Urgent Action
The predicament mirrors past crises like the HIV epidemic, emphasizing the urgent need for global efforts similar to those that fought HIV in Africa’s hotspots. Dr. Jennifer Cohn, a senior study author, stresses that failing to treat these infections not only leads to higher morbidity and mortality rates but also propels AMR further by forcing the use of ineffective antibiotics for longer periods — a link established in several studies.
Did you know?
Consistent with the HIV care cascade model, AMR activists are calling for a similar framework to ensure at least 95% of those infected receive diagnoses and treatment.
Factors Behind the Treatment Gap
Several barriers contribute to this treatment gap. Prevention, diagnosis, and medication affordability remain significant hurdles. Dr. Cohn, alongside her colleagues, underscores the necessity of expanding access to newer antibiotics, not just in affluent nations but globally. This shift requires a dual focus on both innovation and equitable access.
Strategies for Change
To combat these disparities, mechanisms proving effective in tackling HIV, such as the voluntary licensing model that encourages generic drug manufacturing, are under consideration. For instance, the collaboration between GardP and Shionogi aims to boost access to cefiderocol, a drug capable of treating some resistant infections.
What Role Can We All Play? Your Role in Combating AMR
Pro tip: Supporting global health policies and awareness initiatives can contribute to equitable antibiotic access worldwide.
Frequently Asked Questions
What is antimicrobial resistance (AMR)?
AMR occurs when bacteria, viruses, fungi, and parasites evolve to resist the medications designed to combat them, leading to persistent infections and increased mortality.
How does antibiotic misuse contribute to AMR?
Overuse and misuse in low- and middle-income countries allow bacteria exposure to antibiotics, giving pathogens more chances to develop resistance, which exacerbates the AMR crisis.
What is being done to improve access to antibiotics?
Efforts include policy changes for equitable drug distribution, innovative voluntary licensing for generic drugs, and replicating successful healthcare strategies, such as the HIV care cascade model.
Take Action Now
Join the global conversation around AMR by supporting initiatives that promote equitable antibiotic access. Subscribe to stay informed about breakthroughs and advocacy efforts. Together, we can make a difference.
Related reading